arrow
R

Richard A. Larson

university of chicago
H指数:147
被引数:11.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term Follow-up of a Pediatric Regimen for AYA with Ph-negative ALL: 10-year Survival of CALGB 10403 (Alliance)

AYA伴Ph阴性ALL的儿科方案长期随访:CALGB 10403 (Alliance) 10年生存率

2026-05-120
OAAI
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in ASC4FIRST

Asciminib在asc4首先在新诊断的慢性粒细胞白血病中表现出优异的疗效和安全性

Blood
IF23.1
2025-12-170
OAAI
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies

复发/难治性急性白血病接受revumenib治疗的患者结局,重点关注revumenib治疗后的疗法

2025-10-260
OAAI
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

跨大陆成人急性髓系白血病的多维分析揭示了突变景观和治疗结局中的年龄相关趋势(Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

Leukemia
IF13.4
2025-09-190
OAAI
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults

成人TP53突变急性淋巴细胞白血病的临床与分子特征

2025-08-140
OAAI
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study
CANCER
IF5.1
2025-02-061
OAAI
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

10年随访研究:CALGB 10603/Ratify试验中,年龄18-60岁新诊断FLT3突变急性髓系白血病患者的米哚妥林与安慰剂联合强化化疗的比较

BLOOD
IF23.1
2024-11-050
PRE
Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL)

一项关于达沙替尼和伊诺妥单奥唑米星为基础诱导治疗新诊断费城染色体阳性急性淋巴细胞白血病(Ph plus ALL)的II期研究中期结果

BLOOD
IF23.1
2024-11-050
PRE
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years
2024-09-160
PRE
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
LEUKEMIA
IF13.4
2024-01-233
PRE
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults
2023-12-293
OAAI
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
2023-12-266
OAAI
Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
LEUKEMIA
IF13.4
2023-11-289
OAAI
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML
LEUKEMIA
IF13.4
2023-11-079
PRE
Association of social deprivation with survival in younger adult patients with AML: an Alliance study
2023-07-284
OAAI
Outcomes in Patients with FLT3-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

在Gilteritinib与挽救性化疗的3期ADMIRAL试验中接受移植的FLT3-Mutated复发/难治性急性骨髓性白血病患者的结局

2023-04-017
OAAI